C4 therapeutics reports first quarter 2023 financial results and recent business highlights

Preclinical data presented at aacr demonstrated cft1946 is a potent and mutant-selective braf v600 bidac ™ degrader; phase 1/2 clinical trial enrolling patients

CCCC Ratings Summary

CCCC Quant Ranking